Laura Eadie

Laura Eadie

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Dr Laura Eadie is a mid-career researcher having completed her PhD in Medicine in 2013 with a Dean’s Commendation. Laura’s research has always centred on translating laboratory findings to improve patient outcomes. She has spent ten+ years researching modes of resistance to chronic myeloid leukaemia drugs with her efforts resulting in nine first-author publications and presentations at over 25 national and international meetings. She is the tenth recipient of the Peter Nelson Leukaemia Research Fellowship and her research now focuses on high-risk acute lymphoblastic leukaemia (ALL). She is a passionate science communicator and advocate for women in STEM careers. Laura was a 2016 Fulbright Postdoctoral Fellow and was invited to take part in the first TEDx-Fulbright Adelaide event (2019).

Acute Lymphoblastic Leukaemia (ALL) is an extremely heterogeneous disease with subtypes of patients exhibiting a diverse range of genetic mutations. Certain subtypes of ALL can be treated with drugs already in clinical use. Laura undertook her Fulbright fellowship (2016-2017) at St. Jude Children’s Research Hospital in Memphis, Tennessee where she learned mouse models of high-risk ALL. Laura is now leading in vivo mouse studies for high-risk ALL with a specific focus on T-cell ALL. Laura’s research seeks to pave the way for alternative T-ALL therapies that are more effective and have fewer long-term side effects. She is using cutting edge laboratory models to evaluate precision medicine treatment strategies tailored to individual patients. Her current funding will help her and her team create a repository of cells, enabling experimentation and evaluation of the success of different T-ALL targeted therapies.

Long term, Laura aims to provide clinicians with a suite of new and re-purposed FDA-approved drugs, which will be able to effectively treat the different genetic lesions associated with T-ALL.

T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a genomically complex, high-risk disease affecting both children and adults. Novel, targeted treatments are urgently required to prevent drug resistance and relapse. T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge.

Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. The over-arching focus of my studies is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models will be used to (1) examine re-purposing drugs and testing novel therapies; and (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease. Central nervous system (CNS) involvement is common in relapsed ALL but drivers of this aggressive disease are poorly defined. This project will use imaging studies to track specific disease subtypes demonstrating CNS penetration.

Research Project 1 - Dr Laura Eadie

Title: Evaluation of leukaemic invasion and penetrance in mouse models of ALL.

Project description:

Our laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients. Establishment of PDX models from these patient samples is ongoing. Recent PDXs have resulted in leukaemic engraftment within the brain, indicative of CNS involvement and suggesting an aggressive disease. CNS penetration in ALL is a significant un-met clinical need, however, the pathogenesis of CNS disease, the underlying genomic determinants and the biology driving CNS penetration remain poorly understood and targeted therapies are limited.

Additional PDX models resulted in rapid detection of leukaemic cells within the blood, but not the bone marrow or brain, highlight the complexity of individual leukaemias and the need for real-time disease imaging and tracking. Fluorescently-tagged cells harvested from PDX models or transgenic cells harbouring genomic lesions of interest will be used to investigate CNS involvement. Cells isolated from leukaemic organs will be comprehensively characterised using molecular biology and NGS approaches. Surface receptor expression profiles of leukaemic cells will be examined to determine potential causes of invasion. Computational network biology analyses will be performed to define druggable pathways. Results from this project will inform on disease invasion and allow evaluation of treatment strategies for aggressive disease phenotypes in real-time.

Projects available for:  HDR: Mphil / PhD

Location: SAHMRI

Research project start: Semester 1 or 2

Special requirements: Police Clearance

    Expand
  • Appointments

    Date Position Institution name
    2020 Affiliate Senior Lecturer University of Adelaide
    2019 Peter Nelson Post-doctoral Research Fellow SAHMRI
    2016 - 2017 Post-doctoral Research Associate St. Jude Children's Research Hospital
    2014 - 2020 Affiliate Lecturer University of Adelaide
    2013 - 2019 Post-doctoral Researcher SAHMRI
    2013 - 2013 Post-doctoral Researcher SA Pathology
  • Awards and Achievements

    Date Type Title Institution Name Country Amount
    2020 Award American Society of Hematology (ASH) Abstract Achievement Award American Society of Hematology United States
    2020 Award CASS Foundation Travel Grant The CASS Foundation Australia $3500
    2019 Invitation Spot the Bull Science The Science Nation Australia
    2019 Award The Hospital Research Foundation Research Travel Awards The Hospital Research Foundation Australia $4000
    2019 Invitation TEDxFulbright Oration: The Secret Life of a Scientist SAHMR Australia
    2019 Fellowship Peter Nelson Leukaemia Research Fellowship SAHRMI Australia 300000
    2019 Fellowship Cancer Council SA Beat Cancer Project Mid-Career Cancer Research Fellowship (unable to accept) SAHMRI Australia 300000
    2018 Invitation Invited Speaker: Early/Mid-Career Researcher Seminar Series The University of Adelaide Australia
    2016 Invitation Judge: European Molecular Biology Laboratory (EMBL) Australian Postgraduate Symposium (EAPS)
    2016 Invitation Invited Speaker: 18th Annual ESH-iCMLF International Conference on CML – Biology and Therapy
    2016 Invitation Invited Speaker: 18th Annual ESH-iCMLF International Conference on CML – Biology and Therapy
    2016 Scholarship Australian-American Fulbright Postdoctoral Scholarship $38, 500
    2016 Invitation Invited Speaker: International Conference on Cancer Immunology and Immunotherapy
    2016 Fellowship Endeavour Research Fellowship (unable to accept) 23 000
    2013 Award Dean’s Commendation for Doctoral Thesis Excellence
    2011 Award HSANZ Non-Member Travel Grant 1000
    2010 Award HSANZ Non-Member Travel Grant 1500
    2010 Award New Scientist Award for Science and Technology in Society 1000
    2009 Scholarship Leukaemia Foundation of Australia PhD Scholarship 157 500
    2009 Scholarship Dawes Top-up Scholarship 17 500
    2009 Scholarship Baillieu Supplementary Research Scholarship 30 000
    2009 Scholarship NHMRC Biomedical Postgraduate Scholarship (unable to accept) 65 598
    2009 Scholarship Australian Postgraduate Award (unable to accept) 61 281
    2008 Award HSANZ Non-Member Travel Grant 1000
    2006 Award Australasian Society for HIV Medicine Junior Researcher Award
    2006 Scholarship Royal Adelaide Hospital Research Committee Honours Scholarship 5000
    2005 Scholarship Molecular Plant Breeding Cooperative Research Centre Summer Scholarship 1500
    2004 Honour Admittance to the Golden Key International Honour Society
  • Education

    Date Institution name Country Title
    2009 - 2013 University of Adelaide Australia PhD in Medicine
    2006 - 2006 University of Adelaide Australia Honours Degree of Bachelor of Science
    2003 - 2005 University of Adelaide, Adelaide Australia Bachelor of Science
  • Postgraduate Training

    Date Title Institution Country
    2016 - 2017 Fulbright Post-doctoral Research Scholarship St. Jude Children's Research Hospital United States
  • Research Interests

    Expand
  • Journals

    Year Citation
    2021 Heatley, S. L., Asari, K., Schutz, C. E., Leclercq, T. M., McClure, B. J., Eadie, L. N., . . . White, D. L. (2021). In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. Leukemia and Lymphoma, 62(5), 1157-1166.
    DOI
    2021 Tavakoli Shirazi, P., Eadie, L. N., Page, E. C., Heatley, S. L., Bruning, J. B., & White, D. L. (2021). Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia. Cancer Letters.
    DOI
    2020 Forgione, M. O., McClure, B. J., Yeung, D. T., Eadie, L. N., & White, D. L. (2020). MLLT10 rearranged acute leukemia: incidence, prognosis and possible therapeutic strategies. Genes, Chromosomes and Cancer, 59(12), 709-721.
    DOI
    2019 Forgione, M. O., McClure, B. J., Eadie, L. N., Yeung, D. T., & White, D. L. (2019). KMT2A rearranged acute lymphoblastic leukaemia: unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Letters, 469, 410-418.
    DOI Scopus4 WoS4 Europe PMC1
    2019 Tavakoli Shirazi, P., Eadie, L. N., Heatley, S. L., Hughes, T. P., Yeung, D. T., & White, D. L. (2019). The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.. British journal of cancer, 122(4), 455-464.
    DOI
    2018 Eadie, L., Dang, P., Goyne, J., Hughes, T., & White, D. (2018). ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE, 13(1), e0192180-1-e0192180-18.
    DOI Scopus5 WoS6 Europe PMC4
    2018 Eadie, L., Saunders, V., Branford, S., White, D., & Hughes, T. (2018). The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget, 9(17), 13423-13437.
    DOI Scopus14 Europe PMC5
    2018 Eadie, L., Hughes, T., & White, D. (2018). Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia, 32(10), 2288-2291.
    DOI Scopus6 WoS6 Europe PMC1
    2017 Eadie, L., Dang, P., Saunders, V., Yeung, D., Osborn, M., Grigg, A., . . . White, D. (2017). The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia, 31(1), 75-82.
    DOI Scopus29 WoS31 Europe PMC23
    2017 Eadie, L., Hughes, T., & White, D. (2017). Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'. Leukemia, 31(3), 769-770.
    DOI
    2016 Eadie, L., Hughes, T., & White, D. (2016). ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines. PLoS ONE, 11(8), e0161470-1-e0161470-18.
    DOI Scopus20 WoS19 Europe PMC13
    2014 Eadie, L., Hughes, T., & White, D. (2014). Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology & Therapeutics, 95(3), 294-306.
    DOI Scopus48 WoS47 Europe PMC31
    2013 White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204.
    DOI Scopus7 WoS7 Europe PMC6
    2013 Eadie, L., Saunders, V., Hughes, T., & White, D. (2013). Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia & Lymphoma, 54(3), 569-578.
    DOI Scopus16 WoS14 Europe PMC13
    2010 Eadie, L., Hughes, T., & White, D. (2010). Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia, 24(4), 855-857.
    DOI Scopus8 WoS8 Europe PMC8
    2008 Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888.
    DOI Scopus146 WoS132 Europe PMC104
  • Conference Papers

    Year Citation
    2018 Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins.
    DOI
    2015 Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
    2015 Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
    DOI WoS1
    2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology.
    DOI
    2013 Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology.
    DOI
    2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY.
    WoS1
    2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology.
    DOI
    2008 White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY.
    WoS3
    2008 White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology.
    DOI
    2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY.
    WoS7
    2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology.
    DOI
    2005 Keiper, F., Scott, L., Eadie, L., Hayden, M., & Wallwork, H. (2005). Microsatellite (SSR) diversity among Australian Rhynchosporium secalis isolates. In 12th Australian Barley Technical Symposium Conference Proceedings, 11-14 September 2005 [CD-ROM] (pp. 6 pages). Hobart: Australian Barley Association.
    Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020 (n.d.). In HemaSphere Vol. 4 (pp. 1-1168). Ovid Technologies (Wolters Kluwer Health).
    DOI
  • Conference Items

    Year Citation
    2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy.
    2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS).
    2020 Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group.
    2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting).
    2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting).
    2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia.
    2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT.
    2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT.
    2020 Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
    2020 Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
    2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
    2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
    2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference).
    2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference).
    2020 Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY.
    DOI
    2020 Tavakoli, P., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent Activation of JAK/STAT Signaling Plays an Important Role inin VitroJaki Resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY.
    DOI
    2019 Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology.
    DOI
    2019 Tavakoli, P. S., Eadie, L., Heatley, S. L., & White, D. L. (2019). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting 2019. Christchurch, New Zealand.
    2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany.
    2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
    2019 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia.
    2019 Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia.
    2018 Eadie, L. N., Mullighan, C., & White, D. L. (2018). Mutations to the transcription factor MYB alter cellular localization and decrease degradation likely enhancing oncogenicity in patients with T-cell ALL. Poster session presented at the meeting of NDLR.
    2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of ASMR.
    2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of SAHMRI Scientific Seminar.
    2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of 12th Annual Florey postgraduate Conference.
    2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium.
    2016 Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA.
    2016 Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA.
    2016 Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
    DOI WoS1
    2016 Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY.
    DOI
    2016 Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD.
    2016 Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD.
    2016 Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA.
    2016 Leow, B., Eadie, L. N., Leclercq, T., & White, D. L. (2016). Drug resistance in CML: heterogeneity, selection, and clonal architecture. Poster session presented at the meeting of Poster Session. Adelaide, SA.
    2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
    WoS1
    2013 White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA.

Date: January 2019 - December 2021

Project Name: “Preclinical modelling of T-cell Acute Lymphoblastic Leukaemia – defining targeted therapies and preventing treatment resistance

Chief Investigator: Laura Eadie

Funding Body: Peter Nelson Leukaemia Research Fellowship Fund

Amount: $300, 000

 

Date: January 2019 - December 2020

Project Name: “Acute Lymphoblastic Leukaemia: Understanding the factors that determine response to new immune-based therapies

Chief Investigator: Deborah White

Associate Investigator: Laura Eadie

Funding Body: Tour de Cure

Amount: $100, 000

 

Date: January 2017 - December 2018

Project Name: “Using in vivo modelling to investigate therapeutic approaches to reverse/prevent disease resistance in children with high-risk Ph-like B-ALL and T-ALL treated with targeted therapies”

Application Number: 171412

Chief Investigator: Laura Eadie

Associate Investigator: Deborah White

Funding Body: Channel 7 Children’s Research Foundation

Amount: $75, 000

 

    Expand
  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2019 Co-Supervisor Characterising KMT2A and MLLT10 rearranged acute lymphoblastic leukaemia Doctor of Philosophy Doctorate Full Time Miss Michelle Olivia Forgione
    2017 Co-Supervisor Characterising novel genomlc lesions to develop a new comblnatlonal therapeutic strategy, in high-risk acute lymphoblastic leukaemia (ALL) categorized by JAK fusions IL-7R and polycomb repressor complex 2 mutations Doctor of Philosophy Doctorate Full Time Miss Paniz Tavakoli Shirazi
  • Past Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2015 - 2019 Co-Supervisor Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Mr Benjamin Chia Sing Leow
  • Other Supervision Activities

    Date Role Research Topic Location Program Supervision Type Student Load Student Name
    2020 - 2020 Principal Supervisor Investigation of oncogenic fusion genes in leukaemia and evaluation of the efficacy of ABL001 South Australian Health & Medical Research Institute Honours Full Time Elias Lagonik
    2018 - ongoing Principal Supervisor Investigating the efficacy of novel and combination therapies in Ph-like ALL South Australian Health & Medical Research Institute Honours Full Time Caitlin Schutz
    2014 - 2014 Co-Supervisor The effect of the T315I mutation on treatment failure in Chronic Myeloid Leukemia: a mere case of drug binding efficiency? South Australian Health & Medical Research Institute HONOURS DEGREE of BACHELOR OF HEALTH SCIENCES Honours Full Time Benjamin Leow
  • Mentoring

    Date Topic Location Name
    2020 - 2020 Careers Mentoring University of Adelaide Hannah Bonham
    2020 - 2020 Careers Mentoring University of Adelaide Mogana Reckdharajkumar
    Expand
  • Committee Memberships

    Date Role Committee Institution Country
    2020 - 2021 Representative Australian Society for Medical Research SA Committee Australian Society for Medical Research Australia
    2019 - 2019 Treasurer Australian Society for Medical Research SA Committee Australian Society for Medical Research Australia
  • Memberships

    Date Role Membership Country
    2017 - ongoing Member National Postdoctoral Association United States
    2016 - ongoing Member Australian Society for Medical Research (ASMR) Australia
    2015 - 2016 Member YWCA
    2006 - 2007 Member Australasian Society for HIV Medicine (ASHM) Australia
  • Presentation

    Date Topic Presented at Institution Country
    2019 - 2019 The Secret Life of a Scientist TEDxFulbright, Adelaide 2019 South Australian Health & Medical Research Institute Australia

Connect With Me
External Profiles